October 21, 2019
Verseau launches with $50M to develop first-in-class macrophage-targeted immunotherapies and appoints George Golumbeski as Chairman of the Board
Verseau has launched with $50M to work on PSGL-1, which has been identified as lead macrophage checkpoint modulator (MCM) program…